ニュース

リッチモンド社、Beam Therapeuticsと共にα1アンチトリプシン欠乏症（AATD）の画期的な試験を実施

リッチモンドは、Beam Therapeutics が実施中の第1/2相試験において、α1アンチトリプシン欠乏症（AATD）の新たな治療法候補に関する最初の3つの用量レベルの予備的結果が得られたことを発表

リッチモンド、サステナビリティ・アクセラレータープログラムを通じてESGへの取り組みを強化  

私たちは、責任ある持続可能なビジネス成長を促進するために、環境・社会・ガバナンス（ESG）の原則を臨床研究業務に組み込むことに取り組んでいます。

心臓安全性試験を革新する可能性を持つ臨床試験 — 研究コンソーシアムが参画機関を募集

米国を拠点とするCardiac Safety Research Consortium（心臓安全性研究コンソーシアム）は、薬剤の定型的使用を置き換えることを目的としたプロジェクトを支援しました。

リッチモンド、タクシードライバーに救命のための心肺蘇生法（CPR）トレーニングを実施  

リッチモンドはこのたび、乗客の命を救うことを目的として、タクシードライバーに心肺蘇生法（CPR）を教える初のトレーニングプログラムを実施しました。

リッチモンド・ファーマコロジーは、 Matej Goricar医師およびAmir Majid医師の昇進を発表

リッチモンドは、Matej Goricar医師およびAmir Majid医師が、メディカル・ディレクター職内での**上級職（アソシエイト・メディカル・ディレクター）**に昇進したことをお知らせいたします。

リッチモンド、「Restart a Heart Day（心臓リスタート・デイ）」に合わせてCPRトレーニングを開催

リッチモンドは本日、**10月16日（水）に開催された「Restart a Heart Day（リスタート・ア・ハート・デー）」**に参加しました。

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

Richmond promotes new Director of Communications and Participant Engagement

Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement.

Richmond Chief Medical Director calls for a ‘toolbox’ of standards and guidelines for clinical trials

The British Journal of Clinical Pharmacology has published an editorial by Richmond’s Dr Ulrike Lorch and Professor Charles Vincent of Oxford University calling for a ‘toolbox’ of practical standards and guidelines for early phase clinical trials.

リッチモンドが心血管疾患への新たなアプローチの先駆者であるヴァーヴ・セラピューティック社のHeart-2試験に最初の被験者を登録

Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.

A first of a kind trial in the fight against malaria

Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.

Patient with rare bleeding disorder becomes first to test new treatment

The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.

Announcement of Jorg Becoming President Elect

Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.

Single-dose gene silencing cure for fatal heart disease comes one step closer

Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis

Ensuring The Future Of The Experienced Investigator Is Ingrained In Good Clinical Practice Guidance

The ICH Expert Working Group has been revising the Good Clinical Practice (GCP) guideline, ICH E6 (GCP) R3.

Powering STEM Dreams: Snowsfield's Exciting Tour of Richmond Pharmacology

Richmond Pharmacology recently welcomed STEM leaders from Snowsfield Primary School, marking a follow-up to our donation of STEM books for their library.

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

Groundbreaking research paper authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel.

Richmond Pharmacology becomes Richmond in Brand Refresh

Refreshed brand reflects company’s growth over 22 years and renewed commitment to turning hope into reality for patients.

Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)

For patients with heart failure and congestion, vasodilation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload.

Richmond Pharmacology at the Forefront of Groundbreaking Gene-Editing Clinical Trials

Richmond Pharmacology proudly announces its pivotal role in a ground breaking gene-editing clinical trial for heart disease.

Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: Impending change, innovations and future challenges.

The AHPPI conference unfolded as a dynamic exploration of the ever-evolving landscape of early phase clinical drug development.

Richmond Pharmacology Boosts Snowsfields School Library with STEM Book Donation on World STEM Day 2023

Snowsfields School Library has received 50 books about science, technology, engineering and maths (STEM) thanks to a donation from Richmond Pharmacology

A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).

A Prospective, Observational Study of Bleeding and Quality of Life in Patients with Glanzmann Thrombasthenia in the United Kingdom: Updated Results

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023).

Employee Well-Being: A Commitment that Defines Richmond

Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.

Promising Results for Zilebesiran in Phase 1 Study

We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic.

Engaging Hearts and Hands: A Day of Volunteering at Arc Nursery

Discover how Richmond's dedicated team of volunteers is making a positive impact on young minds at Arc Nursery

Exciting Research Update: Enhancing Blinding in Clinical Trials with Auto-Injectors

We’re excited to share the findings of our recent study on the use of auto-injector systems (A-INJ) in randomized controlled trials (RCTs) by Dr Jorg Taubel, Dr Ulrike Lorch, Dr Thomas York and Vishal Aggarwal.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Our research on behalf of Anylam Pharmaceuticals for a novel anti-hypertensive injectable, Zilbesiran, has been featured in the prestigious New England Journal of Medicine.

James Rickard appointed Chief Scientific Officer of Richmond Research Institute

James Rickard is a Research Pharmacist and has been involved in translational research to deliver new therapeutic options to patients throughout his career. Driven by his desire for better outcomes for patients, he spent his early career working across several London Teaching Hospitals in Clinical Pharmacy, Drug Manufacture and Clinical Trials, culminating in taking up the role of Deputy Chief Pharmacist for Barts Health NHS Trust.

Richmond Pharmacology at the BCS 2023 conference

Read more about how Richmond Pharmacology have supported the British Cardiovascular Society this month

Celebrating Clinical Trials Day 2023

This year, we will be celebrating Clinical Trials Day alongside our workforce, sponsors and industry colleagues.

Bridging the gap in Phase 1 clinical studies

Here at Richmond Pharmacology, we focus mainly on Japanese cohorts in order to fast track global marketing authorisations in these important markets, ultimately reaching patients sooner.

Futureproofing early phase clinical research for the next generation of investigators.

Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.

How Does Social Time Contribute to a Positive Workplace Culture?

Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.

Unlocking the potential of data sharing

Dilshat Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry.

How telemonitoring can revolutionise the way we treat patients – Tom York

Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management

Transforming clinical trials to accelerate drug development – Keith Berelowitz

Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.

Clinical trials and the patient perspective

Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.

Clinical trials: how taking the pills can pay those bills.

The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers

NTLA-2001 demonstrates positive results for Intellia Therapeutics and Regeneron Pharmaceuticals

The latest interim data released indicates a promising future for ATTR patients.

How the innovative use of data is transforming clinical research

Dr. Dilshat Djumanov, Director of Data Science at Richmond Pharmacology, outlined the evolution of data management in clinical research and how this aids faster results and greater efficiencies.

The future of clinical workforce training programmes, an exclusive interview with MedCity

Ulrike Lorch discusses the future of clinical workforce training programmes in an exclusive interview with MedCity

Richmond Pharmacology’s Dr Emma Akuffo joins fellow EUCROF task force members as a finalist at TOPRA Awards 2021

EUCROF task force members compete for a prize at the TOPRA Awards 2021

Dr Ulrike Lorch joins the leadership team at the Faculty of Human Pharmacology

Richmond Pharmacology’s Medical Director, Dr Ulrike Lorch, has been appointed Director of Human Pharmacology for the Faculty of Pharmaceutical Management (FPM).

Developing talent in the fast-changing clinical research environment

In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development

The future of new medicine development and first-in-human studies

Dr Jorg Taubel outlines the future of new medicine development, influenced by the emergence of gene based therapies and reshaping first-in-human study design.

Focal epilepsy treatment progresses following positive Phase IIb results

Richmond Pharmacology’s research partner, Xenon Pharmaceuticals reported positive top line results from its Phase IIb X-TOLE clinical trial of XEN1101 – a differentiated Kv7 potassium channel modulator.

Making gains in drug development

Keith Berelowitz outlines the innovations in the design and delivery of clinical trials

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.

Richmond Pharmacology listed in the Alantra Pharma Fast 50

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.

What 20 years of clinical research has taught us about our industry and the future of drug development

As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.

Do we still need challenge trials with COVID-19?

Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.

A new era for UK-Japanese scientific relations

Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London

Richmond Pharmacology supports Codiak BioSciences in the development of a new medicine to help patients with cutaneous T cell lymphoma.

Richmond Pharmacology were pleased to provide our sponsor, Codiak BioSciences, with positive results of its exosome therapeutic exoIL-12.

Contributing to our community in 2020

Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.

Marking a milestone for gene editing

We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)

Richmond Pharmacology supports ReViral with the development of Sisunatovir

ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

Richmond Pharmacology early phase drug development update.

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.

COVID-19 – External Monitoring Guidelines

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Statement: COVID-19

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

First transdermal patch to treat schizophrenia hits market

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Richmond Pharmacology supporting clinical facilities in Nicaragua

Richmond Pharmacology have developed a resourceful way to use study equipment to help reduce waste produced on site and support clinical facilities in under developed nations.

Charitable Contributions in 2019

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic

Richmond Pharmacology to provide Immediate Life Support (ILS) Courses

In line with our on-going commitment to providing quality training and promoting the highest safety standard, Richmond Pharmacology are pleased to announce that our ILS

Echocardiography Course undertaken at Richmond Pharmacology

Richmond Pharmacology CEO, Dr Jorg Taubel, Franklin Gordon, Resuscitation Simulation & Clinical Skills Practitioner and Dr Simon Coates, Research Physician respectively, all began in-house training...

Richmond Pharmacology, Medical Director, Dr Lorch welcomes new Clinical Pharmacology Apprentice scheme

Significant work has been undertaken to push forward the launch of a new apprentice scheme aimed at raising the profile of this high-level occupation.

Dr Arezina article published in GMP review

Richmond Pharmacology’s Research Director Dr Radivoj Arezina has written a piece for the July edition of GMP Review ‘ The application of GMP and its role in maximising the

Richmond Pharmacology Confirm event with the Department of International Trade

Officially an ILS Resuscitation Council Course Centre

Dr Jorg Taubel attending ACCP in San Diego

DIA, Chicago 2017

Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

New CRO unit facility welcomes first overnight patients

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

Richmond Pharmacology Opens New London Bridge Site

This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.

Accelerated Early Phase Drug Development in the UK and Europe

Hear the latest updates about how early phase studies can be accelerated globally by starting first in human trials in the UK then rapidly progress into Europe. This will give you access to a population of 500 million people.

Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock

Paris, France, September 13, 2016

Futura Medical plc announce headline results from its efficacy study of the Company's novel gel for the treatment of erectile dysfunction

<p></p>

Access 500 million patients. Regulators, sponsors....

Organised by the British Consulate Boston; The Medicines and Healthcare products Regulatory Agency (MHRA), sponsors and investigators came together...

No Triumph Without Trials: The Fight Against Cancer

In the last 70 years, the development of clinical cancer research has been remarkable.

Efficient recruitment in one place

Richmond Pharmacology is recognised globally by sponsors and CROs alike for its competence in patient recruitment.

36th Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

Join us for the 36th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT) taking place 9-11 December 2015 in Tokyo, Japan.

2015 ACCP Annual Meeting

'- San Francisco, CA, 27-29 September

High Court rules that Health Research Authority acted unlawfully over trial transparency

<p></p>

6th AGAH Dermatological Product Development Workshop Highlights

As a contributing sponsor Richmond Pharmacology recently attended the 6th AGAH Dermatological Product Development Workshop held June 23-24, 2015, in London, UK.

Local volunteers play valuable role in developing new medicines in Croydon

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

AGAH Annual Meeting 2014 Mitigating risks in early medicines development

A volunteer panel the size of a city...

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.